Botanical Drug Sponsors Would Benefit From Simpler Indications – FDAer
This article was originally published in The Tan Sheet
Executive Summary
Sponsoring botanical drug products with indications for less complex diseases - especially those that are currently without effective treatment - could speed up FDA's review of new botanical drugs, according to Shaw Chen, MD, PhD, Associate Director of CDER's Office of Drug Evaluation I
You may also be interested in...
FDA Botanical Review Team Clears Green Tea-Based Drug As First Approval
FDA's Botanical Review Team on Oct. 31 approved its first botanical drug, MediGene's Polyphenon E ointment
FDA Botanical Review Team Clears Green Tea-Based Drug As First Approval
FDA's Botanical Review Team on Oct. 31 approved its first botanical drug, MediGene's Polyphenon E ointment
FDA Botanical Review Team Clears Green Tea-Based Drug As First Approval
FDA's Botanical Review Team on Oct. 31 approved its first botanical drug, MediGene's Polyphenon E ointment